Year 2019, Volume 5, Issue 1, Pages 233 - 235 2019-01-04

Experience of thrombotic microangiopathy unresponsive to therapeutic apheresis

Hilmi Erdem Sümbül [1] , Onur Taktakoğlu [2]

85 291

No abstract available.

plasmapheresis, rituximab, thrombotic microanjiopathy
  • [1] George JN. How I treat patients with thrombotic thrombocytopenic purpura:2010. Blood 2010;116:4060-9.
  • [2] Kremer Hovinga JA, Vesely SK, Terrell DR, Lammle B, George JN. Survival and relapse in patient with thrombotic thrombocytopenic purpura. Blood 2010;115:1500-11.
  • [3] George JN, Woodson RD, Kiss JE, Kojouri K, Vesely SK. Rituximab therapy for thrombotic thrombocytopenic purpura: a proposed study of the Transfusion Medicine/Hemostasis Clinical Trials Network with a systematic review of rituximab therapy for immune-mediated disorders. J Clin Apher 2006;21:49-56.
  • [4] Ling HT, Field JJ, Blinder MA. Sustained response with rituximab in patients with thrombotic thrombocytopenic purpura: a report of 13 cases and review of the literature. Am J Hematol 2009;84:418-21.
  • [5] McDonald V, Manns K, Mackie IJ, Machin SJ, Scully MA. Rituximab pharmakonetics during the management of acute idiopathic thrombotic thrombocytopenic purpura. J Thromb Haemost 2010;8:1201-8.
Primary Language en
Subjects Health Care Sciences and Services
Journal Section Letters to the Editor
Authors

Orcid: 0000-0002-7192-0280
Author: Hilmi Erdem Sümbül (Primary Author)
Institution: Department of Internal Medicine, Adana Numune Training and Research Hospital, Adana, Turkey
Country: Turkey


Orcid: 0000-0002-9017-7760
Author: Onur Taktakoğlu
Institution: Department of Internal Medicine, Altınkoza Hospital, Adana, Turkey
Country: Turkey


Dates

Publication Date: January 4, 2019

EndNote %0 The European Research Journal Experience of thrombotic microangiopathy unresponsive to therapeutic apheresis %A Hilmi Erdem Sümbül , Onur Taktakoğlu %T Experience of thrombotic microangiopathy unresponsive to therapeutic apheresis %D 2019 %J The European Research Journal %P -2149-3189 %V 5 %N 1 %R doi: 10.18621/eurj.389830 %U 10.18621/eurj.389830